research use only

Sovleplenib Syk inhibitor

Name: Sovleplenib
Brand: Selleck Chemicals
SKU: E4580
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E4580

Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL).

Chemical Structure

Molecular Weight: 482.60

Jump to

Quality Control

Batch: Purity: 99.80%

99.80

Related Targets	EGFR VEGFR FGFR PDGFR c-Met Src MEK CSF-1R FLT3 HER2
Other Syk Inhibitors	R406 R406 (free base) PRT062607 (P505-15) HCl Entospletinib (GS-9973) Piceatannol BAY 61-3606 dihydrochloride PRT-060318 2HCl TAK-659 Hydrochloride Lanraplenib (GS-SYK) RO9021

Solubility

In vitro
Batch:

DMSO : 12 mg/mL (24.86 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.700mg/ml (1.45mM)	Taking the 1 mL working solution as an example, add 50 μL of 14 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.250mg/ml (0.52mM)	Taking the 1 mL working solution as an example, add 50 μL of 5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	482.60	Formula	C₂₄H₃₀N₆O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1415792-84-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	Syk 0.025 μM
References	[1] https://ashpublications.org/blood/article/128/22/3970/114272/HMPL-523-a-Novel-SYK-Inhibitor-Showed-Anti-Tumor

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-09-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06291415	WITHDRAWN	Immune Thrombocytopenia; Blood Platelet Disorder; Hematologic Diseases; Purpura, Thrombocytopenic; Purpura; Blood Coagulation Disorder; Thrombotic Microangiopathies; Hemorrhagic Disorders; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Pathologic Processes; Skin Manifestations; Thrombocytopenia; Purpura, Thrombocytopenic, Idiopathic; Primary Immune Thrombocytopenia; ITP - Immune Thrombocytopenia	Hutchmed	2024-04-02	PHASE1
NCT07348133	COMPLETED	Healthy	Hutchmed	2025-12-11	PHASE1
NCT07331194	COMPLETED	Healthy	Hutchmed	2025-10-28	PHASE1
NCT05535933	ACTIVE_NOT_RECRUITING	Warm Antibody Autoimmune Hemolytic Anemia	Hutchmed	2022-09-30	PHASE2; PHASE3
NCT05029635	COMPLETED	Primary Immune Thrombocytopenia (ITP)	Hutchmed	2021-10-27	PHASE3
NCT03779113	TERMINATED	Non Hodgkin Lymphoma	Hutchmed	2019-09-26	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):